Lumexa Imaging Holdings Earnings Call Transcripts
Fiscal Year 2026
-
A leading outpatient imaging provider is accelerating growth through de novo expansion, joint ventures with health systems, and a focus on advanced imaging, supported by operational and AI-driven efficiencies. Recent policy trends and resumed M&A activity are expected to further enhance long-term growth and margin expansion.
-
Q2 saw strong revenue and volume growth, with advanced modalities reaching a record 37.4% of volume and PET volumes up 23.2%. Guidance was reaffirmed, free cash flow hit a record, and new partnerships and technology initiatives are driving expansion.
-
Q1 revenue grew 3% year-over-year to $253 million, with advanced modalities driving 7% volume growth and PET up 23%. Adjusted EBITDA was flat at $51.2 million, impacted by weather and seasonality, but guidance for 2026 remains strong with expected ramp in the second half.
-
Outpatient imaging growth is driven by advanced modalities, technology investments, and targeted de novo expansion. Strong commercial payer mix, transparent JV reporting, and AI-driven workflow improvements support financial performance and capacity growth.
-
Radiology is seeing rapid growth and consolidation, with advanced imaging driving revenue and margin expansion. The company leverages JV partnerships, de novo openings, and a strong commercial payer mix to fuel growth, while maintaining high patient satisfaction and transparent financial reporting.
-
Diagnostic imaging is a large, fast-growing, and fragmented market, with significant opportunities for expansion through de novo centers, joint ventures, and selective M&A. The business leverages technology and AI for efficiency, maintains high satisfaction rates, and targets consistent, capital-efficient growth.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong revenue and Adjusted EBITDA growth, driven by advanced imaging, new center openings, and operational efficiencies. 2026 guidance projects continued growth, with advanced modalities outpacing routine, and a focus on margin expansion and capital discipline.